Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/β-catenin pathway

Oral Oncology

Volumn 45, Issue 6, 2009, Pages 521-525

  Yanamoto, Souichi ^a   Kawasaki, Goro ^a   Yamada, Shin ichi ^a   Yoshitomi, Izumi ^a   Yoshida, Hajime ^a   Mizuno, Akio ^a  

^a Unit of Translational Medicine   (Japan)

Author keywords

catenin; E cadherin; Invasion; p53R2; Small interfering RNA

Indexed keywords

BETA CATENIN; MATRIX METALLOPROTEINASE; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; UVOMORULIN;

ARTICLE; CANCER INVASION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MOUTH CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

BETA CATENIN; CADHERINS; CELL LINE, TUMOR; COLLAGEN; DOWN-REGULATION; DRUG COMBINATIONS; HUMANS; IMMUNOBLOTTING; LAMININ; MATRIX METALLOPROTEINASES; MOUTH NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEOGLYCANS; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING;

EID: 67349101255     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.07.005     Document Type: Article

References (37)

1. Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404 (2000) 42-49
2. Nakamura Y. Isolation of p53-target genes and their functional analysis. Cancer Sci 95 (2004) 7-11
3. Yamaguchi T., Matsuda K., Sagiya Y., Iwadate M., Fujino M.A., Nakamura Y., et al. P53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61 (2001) 8256-8262
4. Byun D.S., Chae K.S., Ryu B.K., Lee M.G., and Chi S.G. Expression and mutation analyses of p53R2, a newly identified p53 target for DNA repair in human gastric carcinoma. Int J Cancer 98 (2002) 718-723
5. Yanamoto S., Kawasaki G., Yoshitomi I., and Mizuno A. Expression of p53R2, newly p53 target in oral normal epithelium, epithelial dysplasia and squamous cell carcinoma. Cancer Lett 190 (2003) 233-243
6. Okumura H., Natsugoe S., Matsumoto M., Mataki Y., Takatori H., Ishigami S., et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 92 (2005) 284-289
7. Yanamoto S., Iwamoto T., Kawasaki G., Yoshitomi I., Baba N., and Mizuno A. Silencing of the p53R2 gene by RNA interference inhibits growth and enhances 5-fluorouracil sensitivity of oral cancer cells. Cancer Lett 223 (2005) 67-76
8. Yanamoto S., Kawasaki G., Yoshitomi I., and Mizuno A. P53, mdm2, and p21 expression in oral squamous cell carcinomas: Relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94 (2002) 593-600
9. Sessions D.G., Lenox J., Spector G.J., Chao C., and Chaudry O.A. Analysis of treatment results for base of tongue cancer. Laryngoscope 113 (2003) 1252-1261
10. Kurokawa H., Zhang M., Matsumoto S., Yamashita Y., Tomoyose T., Tanaka T., et al. The high prognostic value of the histologic grade at the deep invasive front of tongue squamous cell carcinoma. J Oral Pathol Med 34 (2005) 329-333
11. Bryne M., Koppang H.S., Lilleng R., and Kjaerheim A. Malignacy grading of the deep invasive margins of oral squamous cell carcinoma has high prognostic value. J Pathol 166 (1992) 375-381
12. Bryne M., Jenssen N., and Boysen M. Histologic grading in the deep invasive front of T1 and T2 glottic squamous cell carcinomas has high prognostic value. Virchows Arch 427 (1995) 277-281
13. Uramoto H., Sugio K., Oyama T., Hanagiri T., and Yasumoto K. P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res 26 (2006) 983-988
14. Okumura H., Natsugoe S., Yokomakura N., Kita Y., Matsumoto M., Uchikado Y., et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 12 (2006) 3740-3745
15. Liu X., Zhou B., Xue L., Shin J., Tye K., Lin W., et al. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res 12 (2006) 6337-6344
16. O'Donnell R.K., Kupferman M., Wei S.J., Singhal S., Weber R., O'Malley B., et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24 (2005) 1244-1251
17. Kato Y., Uzawa K., Saito K., Nakashima D., Kato M., Nimura Y., et al. Gene expression pattern in oral cancer cervical lymph node metastasis. Oncol Rep 16 (2006) 1009-1014
18. Thorstensen L., Lind G.E., Lovig T., Diep C.B., Meling G.I., Rognum T.O., et al. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 7 (2005) 99-108
19. Zhong L.P., Li J., Zhang C.P., Zhu H.G., Sun J., and Zhang Z.Y. Expression of E-cadherin in cervical lymph nodes from primary oral squamous cell carcinoma patients. Arch Oral Biol 52 (2007) 740-747
20. Ortega P., Moran A., de Juan C., Frias C., Hernandez S., Lopez-Asenjo J.A., et al. Differential Wnt pathway gene expression and E-cadherin truncation in sporadic colorectal cancers with and without microsatellite instability. Clin Cancer Res 14 (2008) 995-1001
21. Hakansson P., Hofer A., and Thelander L. Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 12 (2006) 7834-7841
22. Yoshida T., Haga S., Numata Y., Yamashita K., Mikami T., Ogawa T., et al. Disruption of the p53-p53R2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis. Int J Cancer 118 (2005) 1395-1403
23. Fan H., Huang A., Villegas C., and Wright J.A. The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA 94 (1997) 13181-13186
24. Zhou B.S., Tsai P., Ker R., Tsai J., Ho R., Yu J., et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16 (1998) 43-49
25. Tsai M.H., Chen X., Chandramouli G.V.R., Chen Y., Yan H., Zhao S., et al. Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells. Oncogene 25 (2006) 622-632
26. Hoschuetzky H., Aberle H., and Kemler R. Β-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127 (1994) 1375-1380
27. Barth A.I., Nathke I.S., and Nelson W.J. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol 9 (1997) 683-690
28. Behrens J., von Kries J.P., Kuhl M., Bruhn L., Wedlich D., Grosschedl R., et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 382 (1996) 638-642
29. Nusse R., and Varmus H.E. Wnt genes. Cell 69 (1992) 1073-1087
30. Bhanot P., Brink M., Samos C.H., Hsieh J.C., Wang Y., Macke J.P., et al. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature 382 (1996) 225-230
31. Huelsken J., and Behrens J. The Wnt signaling pathway. J Cell Sci 115 (2002) 3977-3978
32. Orsulic S., Huber O., Aberle H., Arnold S., and Kemler R. E-cadherin binding prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated transactivation. J Cell Sci 112 (1999) 1237-1245
33. Martensson A., Oberg A., Jung A., Cederquist K., Stenling R., and Palmqvist R. Β-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep 17 (2007) 447-452
34. Stamenkovic I. Extracellular matrix remodeling: the role of matrix metalloproteinases. J Pathol 200 (2003) 448-464
35. Birkedal-Hansen H., Moore W.G.I., Bodden M.K., Windsor L.J., Birkedal-Hansen B., Decarlo A., et al. Matrix metalloprotenases: a review. Crit Rev Oral Biol Med 4 (1993) 197-250
36. de Vicente J.C., Fresno M.F., Villalain L., Vega J.A., and Vallejo G.H. Expression and clinical significance of matrix metalloproteinase-2 and matrix metalloproteinase-9 on oral squamous cell carcinoma. Oral Oncol 41 (2005) 283-293
37. Patel B.P., Shah S.V., Shukla S.N., Shah P.M., and Patel P.S. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 29 (2007) 564-572